New dual agonists (GIP/GLP-1) are showing profound impact not only on weight loss and glycemic control but also on cardiovascular outcomes
50 years of age or older and had established, stable, cardiovascular, cerebrovascular, peripheral artery disease, chronic kidney disease or NYHA class II and III heart failure (85% of the enrolled population) or were 60 years of age or older and had other specified risk factors for cardiovascular disease (15% of the enrolled population)
Cancer (2023)
Rapid weight loss or changes in body fat can temporarily alter estrogen levels and the brainovary signaling that drives ovulation, which can shift your cycle
Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction
Herness, S., Zhao, F., Lu, S., Kaya, N